Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease

被引：0
|
作者：
Chua, L. [1 ]
Otani, Y. [1 ]
Friedrich, S. [1 ]
Durand, F. [1 ]
Zhang, X. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1044
引用
收藏
页码：I1873 / I1873
页数：1
相关论文
共 50 条
  • [1] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN A PHASE 2 STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Chua, Laiyi
    Otani, Yuki
    Friedrich, Stuart
    Durand, Frederick
    Zhang, Xin
    GASTROENTEROLOGY, 2024, 166 (05) : S822 - S822
  • [2] Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn's Disease in Phase 2 and 3 Studies
    Chua, Laiyi
    Otani, Yuki
    Friedrich, Stuart
    Durand, Frederick
    Zhang, Xin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1056 - S1056
  • [3] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [4] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy
    Larkin, Amy E.
    Zhang, Xin
    GASTROENTEROLOGY, 2024, 166 (05) : S822 - S823
  • [5] Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study
    Regueiro, Miguel
    Fischer, Monika
    Bossuyt, Peter
    Mcginnis, Kim
    Protic, Marijana
    Hunter Gibble, Theresa
    Panni, Tommaso
    Chan, Lai Shan
    Hibi, Toshifumi
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2024, 31 (02) : 432 - 441
  • [6] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
    Friedrich, S.
    Chua, L.
    Zhang, X. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646
  • [7] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [8] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    GASTROENTEROLOGY, 2022, 162 (03) : S15 - S15
  • [9] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S15 - S15
  • [10] Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104
    Regueiro, Miguel
    Fischer, Monika
    Bossuyt, Peter
    McGinnis, Kim
    Gibble, Theresa Hunter
    Protic, Marijana
    Panni, Tommaso
    Hibi, Toshifumi
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S816
12345